Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex
- 28 November 2012
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 4 (162), 162ra153
- https://doi.org/10.1126/scitranslmed.3004690
Abstract
A monoclonal antibody mimic of FGF21 exerts beneficial metabolic effects in obese monkeys.Keywords
This publication has 39 references indexed in Scilit:
- βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and MetabolismCell Metabolism, 2012
- Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γProceedings of the National Academy of Sciences, 2012
- Endocrine fibroblast growth factors 15/19 and 21: from feast to famineGenes & Development, 2012
- Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of ThiazolidinedionesCell, 2012
- FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 ActivationJournal of Biological Chemistry, 2010
- Relevant use of Klotho in FGF19 subfamily signaling system in vivoProceedings of the National Academy of Sciences of the United States of America, 2010
- Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21Journal of Biological Chemistry, 2007
- Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21Cell Metabolism, 2007
- βKlotho is required for metabolic activity of fibroblast growth factor 21Proceedings of the National Academy of Sciences, 2007
- FGF-21 as a novel metabolic regulatorJCI Insight, 2005